Immatics NV
NASDAQ:IMTX
Intrinsic Value
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. [ Read More ]
The intrinsic value of one IMTX stock under the Base Case scenario is 5.74 USD. Compared to the current market price of 10.15 USD, Immatics NV is Overvalued by 43%.
Valuation Backtest
Immatics NV
Run backtest to discover the historical profit from buying and selling IMTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Immatics NV
Current Assets | 449.4m |
Cash & Short-Term Investments | 425.9m |
Receivables | 5.7m |
Other Current Assets | 17.7m |
Non-Current Assets | 60.6m |
PP&E | 57.1m |
Intangibles | 1.5m |
Other Non-Current Assets | 2m |
Current Liabilities | 156.6m |
Accounts Payable | 25.2m |
Accrued Liabilities | 4.8m |
Other Current Liabilities | 126.5m |
Non-Current Liabilities | 128.3m |
Long-Term Debt | 12.8m |
Other Non-Current Liabilities | 115.5m |
Earnings Waterfall
Immatics NV
Revenue
|
54m
EUR
|
Operating Expenses
|
-155.7m
EUR
|
Operating Income
|
-101.7m
EUR
|
Other Expenses
|
4.7m
EUR
|
Net Income
|
-97m
EUR
|
Free Cash Flow Analysis
Immatics NV
What is Free Cash Flow?
IMTX Profitability Score
Profitability Due Diligence
Immatics NV's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Immatics NV's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
IMTX Solvency Score
Solvency Due Diligence
Immatics NV's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Immatics NV's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMTX Price Targets Summary
Immatics NV
According to Wall Street analysts, the average 1-year price target for IMTX is 19.09 USD with a low forecast of 14.14 USD and a high forecast of 26.25 USD.
Shareholder Return
IMTX Price
Immatics NV
Average Annual Return | -14.47% |
Standard Deviation of Annual Returns | 27.28% |
Max Drawdown | -62% |
Market Capitalization | 1B USD |
Shares Outstanding | 102 990 000 |
Percentage of Shares Shorted | 10.94% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 188 full-time employees. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Contact
IPO
Employees
Officers
The intrinsic value of one IMTX stock under the Base Case scenario is 5.74 USD.
Compared to the current market price of 10.15 USD, Immatics NV is Overvalued by 43%.